Details

Autor(en) / Beteiligte

• Chopra, H K
• Nair, Tiny
• Wander, G S
• Ponde, C K
• Ray, Saumitra
• Khullar, Dinesh
• Nanda, Navin C
• Narula, Jagat
• Kasliwal, Ravi R
• Rana, D S
• Kirpalani, Ashok
• Sawhney, J P S
• Chandra, Praveen
• Mehta, Yatin
• Kumar, Viveka
• Tewari, S
• Pancholia, A K
• Kher, Vijay
• Bansal, Sandeep
• Mittal, Sanjay
• Kerkar, Praful
• Sahoo, P K
• Hotchandani, Ramesh
• Prakash, Sunil
• Chauhan, Nagendra
• Rastogi, Vishal
• Jabir, A
• Shanmugasundaram, S
• Tiwaskar, Mangesh
• Sinha, Ajay
• Gupta, Vittul
• Mishra, S S
• Routray, S N
• Omar, A K
• Swami, Onkar C
• Jaswal, Aparna
• Alam, Shamsad
• Passey, Rajeev
• Rajput, Rajeeve
• Paul, Justin
• Kapoor, Aditya
• Prabhakar, D
• Chandra, Subhash
• Malhotra, Poonam
• Singh, Vivudh Pratap
• Bansal, Manish
• Shah, Priyank
• Jain, Sanjay
• Bhargava, Mohan
• Vijayalakshmi, I B
• Varghaese, Kiron
• Jain, Dharmender
• Goel, Anupam
• Mehmood, Kiran
• Gaur, Namrata
• Tandon, Rohit
• Moorthy, Asha
• George, Sheeba
• Katyal, V K
• Mantri, R R
• Mehrotra, Rahul
• Bhalla, Dilip
• Mittal, Vinod
• Rao, Sarita
• Jagia, Manish
• Singh, Harmeet
• Awasthi, Surabhi
• Sattur, Ameet
• Mishra, Rekha
• Pandey, Anand
• Chawla, Rajeev
• Jaggi, Shalini
• Sehgal, Blessy
• Sehgal, Alok
• Goel, Naresh
• Gupta, Ripen
• Kubba, Samir
• Chhabra, Abhinav
• Bagga, Saurabh
• Shastry, N R

Titel

Current Place of SGLT2i in the Management of Heart Failure: An Expert Opinion from India

Ist Teil von

• Journal of the Association of Physicians of India, 2024-01, Vol.72 (1), p.63

Ort / Verlag

India

Erscheinungsjahr

2024

Quelle

MEDLINE

Beschreibungen/Notizen

• Heart failure (HF) is a global health concern that is prevalent in India as well. HF is reported at a younger age in Indian patients with comorbidity of type 2 diabetes (T2DM) in approximately 50% of patients. Sodium-glucose cotransporter-2 inhibitors (SGLT2i), originally approved for T2DM, are new guideline-recommended and approved treatment strategies for HF. Extensive evidence highlights that SGLT2i exhibits profound cardiovascular (CV) benefits beyond glycemic control. SGLT2i, in conjunction with other guideline-directed medical therapies (GMDT), has additive effects in improving heart function and reducing adverse HF outcomes. The benefits of SGLT2i are across a spectrum of patients, with and without diabetes, suggesting their potential place in broader HF populations irrespective of ejection fraction (EF). This consensus builds on the updated evidence of the efficacy and safety of SGLT2i in HF and recommends its place in therapy with a focus on Indian patients with HF.